Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AstraZeneca PLC | FASENRA (Benralizumab) - (RESOLUTE) | Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations | Phase 3 | Trial Discontinued | Subcutaneous | Respiratory |
| AstraZeneca PLC | Imfinzi (durvalumab) - (ADJUVANT BR.31) | Early-stage (IB-IIIA) non-small cell lung cancer (NSCLC) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| AstraZeneca PLC | Truqap - (CAPItello-290) | Metastatic triple-negative breast cancer | Phase 3 | Data Released | oral | Oncology |
| AstraZeneca PLC | ULTOMIRIS (ravulizumab-cwvz) - (ICAN) | Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) | Phase 3 | Ongoing | Intravenous | Hematology |
| AstraZeneca PLC | IMFINZI (Durvalumab) + TACE - (EMERALD-3) | Locoregional Hepatocellular carcinoma (HCC) | Phase 3 | Data Released | Intravenous | Oncology |
| AstraZeneca PLC | ORPATHYS (savolitinib) + TAGRISSO (osimertinib) - (SAFFRON) | Non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | oral | Oncology |
| AstraZeneca PLC | Sipavibart (AZD3152) - (SUPERNOVA) | COVID‚Äë19 | Phase 3 | Data Released | Intravenous | COVID-19 |
| AstraZeneca PLC | Tezepelumab | Eosinophilic esophagitis (EoE) | Phase 3 | Ongoing | Subcutaneous | Gastroenterology |
